Long-term Survival of Patients with Breast Cancer and Brain Metastases: ‘The experience of the 2^nd Oncology Department of Metropolitan Hospital and a brief review of the literature’

[1] Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer. 2012 May 22;106:1850-3.10.1038/bjc.2012.163336412422531629Search in Google Scholar

[2] Lang EF, Slater J. Metastatic brain tumor: Results of surgical and nonsurgical treatment. Surg. Clin. North Am. 44:865, 1964.Search in Google Scholar

[3] Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist, 2003, 8, 398-410.10.1634/theoncologist.8-5-39814530493Search in Google Scholar

[4] Rorive A, Colliggnon J, Martin M, Andre C, Jerusalem G, Coucke Ph. Cancer du Sein et Metastases cerebrales, Rev Med Liege 2011;66:5-6:299-305Search in Google Scholar

[5] Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.10.1200/JCO.2004.01.17515337811Search in Google Scholar

[6] Chang EL, Lo S. Diagnosis and Management of Central Nervous Metastases from Breast cancer. The Oncologist 2003;8:398-410.10.1634/theoncologist.8-5-398Search in Google Scholar

[7] McCormick B, Abramson DH. Ocular metastases. In:Harris JR, ed Disease of the Breast Philadelphia: Lippincott Williams &Wilkins,2000:889-891.Search in Google Scholar

[8] Evans A, James J, Cornford E, Chan S, Burrell H, Pinder S, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol. 2004;16:345-349.10.1016/j.clon.2004.03.01215341438Search in Google Scholar

[9] Scott B, Kesari S. Leptomeningeal metastases in breast cancer Am J Cancer Res. 2013; 3(2): 117-126.Search in Google Scholar

[10] Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. International Breast Cancer Study Group (IBCSG) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol. 2006;17:935-944.10.1093/annonc/mdl06416603601Search in Google Scholar

[11] Kennecke H, Yerushalmi R, Woods R, Cheang MCV, Voduc D, Speers CH et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol, 2010, 28, 3271-3277.10.1200/JCO.2009.25.982020498394Search in Google Scholar

[12] Lin NU, Dieras V, Paul D, Lossingol D, Christodoulou Ch, Stemmler HJ et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.10.1158/1078-0432.CCR-08-108019228746Search in Google Scholar

[13] Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindther J, Collins J et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.10.1093/annonc/mdl064Search in Google Scholar

[14] Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.10.1002/cncr.2204116826579Search in Google Scholar

[15] Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004 Nov;15:1640-4.10.1093/annonc/mdh432Search in Google Scholar

[16] Heitz F, PH, Traut A, Lueck HJ, Beutel B, du Bois A. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 2008; 26: (Abstr 1010).10.1200/jco.2008.26.15_suppl.1010Search in Google Scholar

[17] Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20:621-627.10.1093/annonc/mdn682Search in Google Scholar

[18] Di Stefano A, Yong Yap Y, Hortobayi GN, George R. The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-1918.10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-DSearch in Google Scholar

[19] Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM. Risk factors and survival outcome in cerebral metastatic breast cancer. Med Oncol. 2014 Mar;31(3):862.10.1007/s12032-014-0862-2Search in Google Scholar

[20] Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 22:3302-3308, 2004Search in Google Scholar

[21] Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-2354.10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-BSearch in Google Scholar

[22] Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother, 2010, 11, 1089-1100.10.1517/14656561003702412Search in Google Scholar

[23] Wen PY, Shafman TD. Site-specific therapy of metastatic breast cancer. In: Harris JR, ed. Disease of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2000:841-853.Search in Google Scholar

[24] Rubinstein AB, Schein M, Reichenthal E. The association of carcinoma of the breast with meningioma. Surg Gynecol Obstet 1989;169:334-336.Search in Google Scholar

[25] Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975;25:705-712.10.1212/WNL.25.8.705Search in Google Scholar

[26] Peretti-Viton P, Margain D, Murayama N, Kadr I, Peragut JC. Brain metastases. J Neuroradiol 1991;18:161-172.Search in Google Scholar

[27] Chang EL, Hassenbusch SJ, Shiu A, Lang FF, Allen PK, Sawaya R et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003;53:272-281.10.1227/01.NEU.0000073546.61154.9ASearch in Google Scholar

[28] Loeffler J, Alexander E. Radiosurgery for the treatment of intracranial metastases. In: Loeffler JS, ed. Stereotactic Radiosurgery. New York: McGraw- Hill, 1993:197-206.Search in Google Scholar

[29] Order SE, Hellman S, Von Essen CF, Kligerman MM. Improvement in quality of survival following wholebrain irradiation for brain metastasis. Radiology 1968;91:149-153.10.1148/91.1.149Search in Google Scholar

[30] West J, Maor M. Intracranial metastases: behavioral patterns related to primary site and results of treatment by whole brain irradiation. Int J Radiat Oncol Biol Phys 1980;6:11-15.10.1016/0360-3016(80)90196-0Search in Google Scholar

[31] DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24:798-80510.1227/00006123-198906000-000022473409Search in Google Scholar

[32] Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 1990;8:576-582.10.1200/JCO.1990.8.4.5762179476Search in Google Scholar

[33] Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18:2349-2351.10.1200/JCO.2000.18.11.234910829059Search in Google Scholar

[34] Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CL. Effects of the EGFR/HER2 kinase inhibitor W572016 on EGFR- and HER2- overexpressing breast cancer cell line Proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344-352, 200410.1016/j.ijrobp.2003.09.04614751502Search in Google Scholar

[35] Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22 (3): 625-630.10.1093/annonc/mdq43420724575Search in Google Scholar

[36] Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab- Refractory Metastatic Breast Cancer JCO March 1, 2010 vol. 28 no. 7 1124-113010.1200/JCO.2008.21.443720124187Search in Google Scholar

[37] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom K,Fehrenbacher L, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer JCO February 1, 2005 vol. 23 no. 4 792-79910.1200/JCO.2005.05.09815681523Search in Google Scholar

[38] Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolamide in heavily ptretreated cancer patients with brain metastases. Annals of Oncology 2001;12:249-251.10.1023/A:1008354323167Search in Google Scholar

[39] Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17:952-6.10.1093/annonc/mdl05616565212Search in Google Scholar

[40] Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol. 2005;71:61-5.10.1007/s11060-004-9176-015719277Search in Google Scholar

[41] Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, et al. miR-7 suppresses brain metastasis of breast cancer stem like cells by modulating KLF-4. Cancer Res. 2013;73(4):1434-44.10.1158/0008-5472.CAN-12-2037357613823384942Search in Google Scholar

[42] Alsidawi S, Malek E and Driscoll J. MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. Int. J. Mol. Sci. 2014;15: 10508-10526.Search in Google Scholar

[43] Zhang S, Huang WC, Zhang L, Cancer Brain Metastases Src Family Kinases as Novel Therapeutic Targets to Treat Breast. Cancer Res. 2013;73:5764-5774.10.1158/0008-5472.CAN-12-1803378159223913825Search in Google Scholar

[44] Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis. Sci Transl Med. 2013;180(5):180ra48.10.1126/scitranslmed.3005109386390923576814Search in Google Scholar

[45] https://clinicaltrials.gov/ct2/results?term=breast+ca ncer+and+brain+metastases&recr=Open&pg=1 Search in Google Scholar